InspireMD Q1 FY26 net loss widens 22.6% to $13.69 million; revenue more than doubles to $3.4 million

InspireMD Inc.

InspireMD Inc.

NSPR

0.00
  • InspireMD posted Q1 revenue of USD 3.4 million, up more than doubled, while net loss widened 22.6% to USD 13.69 million.
  • Gross margin edged up 1.1 percentage points to 20.2%, as gross profit rose to USD 687,000 despite a USD 473,000 inventory-obsolescence impairment tied to the CGuard Prime delivery system.
  • Research and development expense climbed 17.4% to USD 4.76 million, while selling and marketing expense jumped 88.4% to USD 5.18 million on higher U.S. commercial staffing.
  • Cash and cash equivalents totaled USD 11.36 million, while marketable securities were USD 30.21 million; operating cash outflow increased 40.3% to USD 12.34 million.
  • Company announced a voluntary U.S. recall of CGuard Prime in consultation with FDA, expecting reserves of about USD 700,000 for customer returns and about USD 650,000 for inventory impairment and remediation costs.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InspireMD Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-021636), on May 07, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.